U.MIR PHARMA LTD

Company Registration Number:
07321929 (England and Wales)

Unaudited abridged accounts for the year ended 31 July 2023

Period of accounts

Start date: 01 August 2022

End date: 31 July 2023

U.MIR PHARMA LTD

Contents of the Financial Statements

for the Period Ended 31 July 2023

Balance sheet
Notes

U.MIR PHARMA LTD

Balance sheet

As at 31 July 2023


Notes

2023

2022


£

£
Fixed assets
Intangible assets: 3 17,779 21,543
Tangible assets: 4 198,914 85,501
Total fixed assets: 216,693 107,044
Current assets
Stocks: 85,000 98,000
Debtors: 5 228,664 249,641
Cash at bank and in hand: 7,546 111,649
Total current assets: 321,210 459,290
Creditors: amounts falling due within one year:   (274,617) (221,753)
Net current assets (liabilities): 46,593 237,537
Total assets less current liabilities: 263,286 344,581
Creditors: amounts falling due after more than one year:   (159,016) (259,775)
Total net assets (liabilities): 104,270 84,806
Capital and reserves
Called up share capital: 2,002 2,002
Profit and loss account: 102,268 82,804
Shareholders funds: 104,270 84,806

The notes form part of these financial statements

U.MIR PHARMA LTD

Balance sheet statements

For the year ending 31 July 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 10 November 2023
and signed on behalf of the board by:

Name: USMAN MIR
Status: Director

The notes form part of these financial statements

U.MIR PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

U.MIR PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

2. Employees

2023 2022
Average number of employees during the period 13 13

U.MIR PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

3. Intangible Assets

Total
Cost £
At 01 August 2022 37,635
At 31 July 2023 37,635
Amortisation
At 01 August 2022 16,092
Charge for year 3,764
At 31 July 2023 19,856
Net book value
At 31 July 2023 17,779
At 31 July 2022 21,543

U.MIR PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

4. Tangible Assets

Total
Cost £
At 01 August 2022 206,989
Additions 147,641
At 31 July 2023 354,630
Depreciation
At 01 August 2022 121,488
Charge for year 34,228
At 31 July 2023 155,716
Net book value
At 31 July 2023 198,914
At 31 July 2022 85,501

U.MIR PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2023

5. Debtors

2023 2022
££
Debtors due after more than one year: 228,664 249,641